Published in Biomaterials on July 14, 2016
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. Vaccines (Basel) (2016) 0.78
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 12.70
Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature (1998) 11.08
Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med (1996) 9.31
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
CD40-CD40 ligand. J Leukoc Biol (2000) 6.28
Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature (2006) 5.54
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
DNA-assisted dispersion and separation of carbon nanotubes. Nat Mater (2003) 4.65
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol (2010) 4.06
Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med (1997) 4.01
Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol (2006) 3.57
Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials (2010) 3.54
CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol (2004) 3.36
Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov (2010) 3.35
Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science (2007) 3.27
Carbon nanotubes as intracellular transporters for proteins and DNA: an investigation of the uptake mechanism and pathway. Angew Chem Int Ed Engl (2006) 3.17
Biomedical applications of functionalised carbon nanotubes. Chem Commun (Camb) (2004) 3.10
Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat Nanotechnol (2007) 2.57
Toll-like receptor recognition regulates immunodominance in an antimicrobial CD4+ T cell response. Immunity (2006) 2.05
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene (2008) 1.94
The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials (2009) 1.82
Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol (2000) 1.76
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood (2012) 1.43
Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity. Eur J Immunol (2007) 1.33
Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur J Immunol (2001) 1.33
TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine (2008) 1.26
Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation. J Exp Med (2013) 1.25
Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J Immunother (2007) 1.24
Dendritic cell-targeted vaccines--hope or hype? Nat Rev Immunol (2014) 1.17
Carbon nanotubes conjugated to tumor lysate protein enhance the efficacy of an antitumor immunotherapy. Small (2008) 1.17
Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity. Clin Cancer Res (2010) 1.14
CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials (2014) 1.08
In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines. Mol Pharm (2009) 1.02
Cationic carbon nanotubes bind to CpG oligodeoxynucleotides and enhance their immunostimulatory properties. J Am Chem Soc (2005) 1.02
A carbon nanotube-polymer composite for T-cell therapy. Nat Nanotechnol (2014) 0.93
Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J Immunol (1997) 0.92
Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine (2003) 0.91
Uptake and transport of PEG-graft-trimethyl-chitosan copolymer-insulin nanocomplexes by epithelial cells. Pharm Res (2005) 0.88
Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice. Clin Cancer Res (2012) 0.88
Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity. PLoS One (2012) 0.87
Multivalent porous silicon nanoparticles enhance the immune activation potency of agonistic CD40 antibody. Adv Mater (2012) 0.85
Multi-walled carbon nanotubes conjugated to tumor protein enhance the uptake of tumor antigens by human dendritic cells in vitro. Cell Res (2010) 0.82
Oxidized multiwalled carbon nanotubes as antigen delivery system to promote superior CD8(+) T cell response and protection against cancer. Nano Lett (2014) 0.82
The devil and holy water: protein and carbon nanotube hybrids. Acc Chem Res (2013) 0.81
Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticles. Biomaterials (2012) 0.80
Liposomal co-entrapment of CD40mAb induces enhanced IgG responses against bacterial polysaccharide and protein. PLoS One (2008) 0.80
Gold nanocluster-based vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. Nanoscale (2015) 0.79
Carbon nanotubes' surface chemistry determines their potency as vaccine nanocarriers in vitro and in vivo. J Control Release (2016) 0.76
Carbon nanotubes' surface chemistry determines their potency as vaccine nanocarriers in vitro and in vivo. J Control Release (2016) 0.76
Functionalised carbon nanotubes: From intracellular uptake and cell-related toxicity to systemic brain delivery. J Control Release (2016) 0.75